Filing Flows › Davita (DVA) › Q3 2026 › vs Q2 2026
Davita (DVA) Q3 2026 vs Q2 2026 (quarter over quarter)
Davita's revenue rose $24.0M (+0.7%) from $3.6B in Q2 2026 to $3.6B in Q3 2026. The biggest changes: U. S. Dialysis and Related Lab Services +$28.0M (+0.9%); Other - Ancillary Services −$4.0M (-0.7%). Operating margin 14.0% against 16.3% (-2.3 pts).
Davita, Q3 2026: revenue $3.6B (+5% year over year), operating margin 14.0%, net earnings $223M, operating cash flow $519M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 14.0% | 16.3% | -2.3 pts |
| Net margin | 6.2% | 7.5% | -1.2 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| U. S. Dialysis and Related Lab Services | $3.0B | $3.0B | $28.0M | +0.9% |
| Other - Ancillary Services | $550M | $554M | −$4.0M | -0.7% |
| Revenue | $3.6B | $3.6B | $24.0M | +0.7% |
| Operating profit | $499M | $579M | −$79.7M | -14% |
| Costs & expenses | $3.1B | $3.0B | $104M | +3% |
| Pre-tax earnings | $359M | $435M | −$76.3M | -18% |
| Other expense, net | $141M | $144M | −$3.4M | -2% |
| General & admin | $409M | $423M | −$14.8M | -3% |
| Other operating costs | $2.7B | $2.6B | $119M | +5% |
| Net earnings | $223M | $265M | −$42.5M | -16% |
| Minority interests | $46.5M | $77.8M | −$31.4M | -40% |
| Income tax | $89.3M | $91.8M | −$2.5M | -3% |
| Depreciation & amortization | $165M | $168M | −$2.6M | -2% |
| Share-based compensation | $29.2M | $26.0M | $3.2M | +12% |
| Working capital & other | $102M | $30.8M | $70.7M | +229% |
| Operating cash flow | $519M | $490M | $28.8M | +6% |
Questions
How much did Davita's revenue grow quarter over quarter in Q3 2026?
Davita's revenue rose $24.0M (+0.7%) from $3.6B in Q2 2026 to $3.6B in Q3 2026.
What drove Davita's revenue change in Q3 2026?
U.